← Back to Clinical Trials
Recruiting NCT04095195

NCT04095195 Registry of Subjects at Risk of Pancreatic Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04095195
Status Recruiting
Phase
Sponsor Associazione Italiana per lo Studio del Pancreas
Condition Familial Pancreatic Cancer
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2019-08-20
Primary Completion 2044-08-20

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL
Interventions
MRCPEndoultrasonography

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2019-08-20 with a primary completion date of 2044-08-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.

Eligibility Criteria

Inclusion Criteria to enter the registry: * individuals with at least two relatives suffering from pancreatic cancer, with at least 1 first-degree and until the third-degree * subjects with known genetic mutation of BRCA2, BRCA1, p16, PALB2 with at least 1 first- or 2nd-degree relative suffering from pancreatic cancer * subjects suffering from FAMMM Syndrome * subjects suffering from Peutz-Jeghers Syndrome * subjects suffering from PRSS-1- or CFTR- or SPINK-1- related pancreatitis * subjects suffering from Lynch syndrome with at least 1 first- or 2nd-degree relative suffering from pancreatic cancer Inclusion criteria to join the "radiologic follow-up": * 45 years or 10 years younger than the youngest index case of pancreatic cancer in the family for familial cases * 40 years or 5 years younger than the youngest index case of pancreatic cancer for subjects suffering from hereditary/genetic pancreatitis, Lynch syndrome, or carrying a known BRCA 1/2, PALB2, p16 genetic mutation with familiarity for pancreatic cancer * 30 years for subjects suffering from FAMMM, Peutz-Jeghers syndrome Exclusion Criteria: \- pregnancy

Contact & Investigator

Central Contact

Salvatore Paiella, MD, PhD

✉ salvatore.paiella@univr.it

📞 00390458126009

Frequently Asked Questions

Who can join the NCT04095195 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Familial Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04095195 currently recruiting?

Yes, NCT04095195 is actively recruiting participants. Contact the research team at salvatore.paiella@univr.it for enrollment information.

Where is the NCT04095195 trial being conducted?

This trial is being conducted at Rozzano, Italy, Peschiera del Garda, Italy, Milan, Italy, Verona, Italy.

Who is sponsoring the NCT04095195 clinical trial?

NCT04095195 is sponsored by Associazione Italiana per lo Studio del Pancreas. The trial plans to enroll 1,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology